Recall issued for Lacri-Lube eye drops
Allergan is recalling affected batches of its dry eye treatment due to black particles on or near the nozzle which could potentially enter the eye
21 September 2015
The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall notice for batches of Lacri-Lube eye ointment.
The recall notice relates to 5g and 3.5g pack sizes, which manufacturer Allergan is recalling due to complaints of black particles on or around the nozzle of the tube.
The particles are believed to be the result of over-tightening of the cap during the manufacturing process, and could potentially enter the eye when the drops are administered.
Remaining stock of affected batches should be quarantined and returned to supplier. Allergan has advised that stock supply could potentially be affected until early 2016.
Full details of affected batches are available on the gov.uk website.
For medical information enquiries, contact Allergan Medical Information by telephone on 01628 494 026 or email.
- Specsavers introduces new clinical technician role to the group
- Johnson & Johnson Vision secures approval for Acuvue Oasys Max 1-Day
- Vision screening in older adults does not identify risky drivers
- The evolving scope of hospital optometry
- “The pandemic has shown us that the optometry and ophthalmology sectors can work together”